Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Anwaar Saeed

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8024-9401; OpenAlex author ID A5048681236, A5111225640. Sources: ClinicalTrials.gov.

Their work

Papers
12 (first author 1, last author 4)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
2
Collaborators
44
Papers, trials and grants by year

2020: 1 paper · 2021: 2 papers · 2022: 1 trial · 2023: none · 2024: 1 paper · 2025: 5 papers, 1 trial · 2026: 3 papers

Papers 12

  1. Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial. Co-author DOI 10.1038/s41591-026-04283-z↗
  2. Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): a phase II study (NIRA-PANC). Co-author DOI 10.1093/oncolo/oyag225↗
  3. KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18633-7↗
  4. Optimizing Perioperative Management of Pancreatic Ductal Adenocarcinoma: Insights Into Modified FOLFIRINOX Relative Dose Intensity and CA 19-9 Dynamics. Co-author DOI 10.1002/jso.70057↗
  5. Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2. Last author DOI 10.1016/j.canlet.2024.217362↗
  6. Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic … First author DOI 10.1016/j.esmoop.2025.105122↗
  7. ASO Visual Abstract: KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Associations with Survival in Localized Pancreatic Adenocarcinoma Co-author DOI 10.1245/s10434-025-18842-0↗
  8. The Role of ENHO in Pancreatic Adenocarcinoma: A Bioinformatics Approach. Last author DOI 10.3390/cancers17132139↗
  9. Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational s… Co-author DOI 10.1016/j.esmogo.2024.100042↗
  10. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Last author DOI 10.1016/j.ctarc.2021.100342↗
  11. GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties. Last author DOI 10.3390/biology10070610↗
  12. Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer. Co-author DOI 10.3390/jcm9103283↗

Trials 2

  1. 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) Principal investigator NCT06896188↗
  2. 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma Principal investigator NCT05239182↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 3 shared papers, 2025–2026 · strength 0.69
  2. Aatur Dilip Singhi · 3 shared papers, 2025–2026 · strength 0.69
  3. Alessandro Paniccia · 3 shared papers, 2025–2026 · strength 0.69
  4. Siyang Zheng · 2 shared papers, 2025–2026 · strength 0.44
  5. Asmita Chopra · 2 shared papers, 2025–2026 · strength 0.44
  6. Ibrahim Nassour · 2 shared papers, 2025–2026 · strength 0.44
  7. Alireza Tojjari · 1 shared paper, 2025 · strength 0.42
  8. Gulam Abbas Manji · 2 shared papers, 2024–2026 · strength 0.39
  9. Ludimila L. Cavalcante · 2 shared papers, 2021–2025 · strength 0.38
  10. Andrew L. Coveler · 2 shared papers, 2021–2025 · strength 0.38
  11. Robin Park · 2 shared papers, 2021 · strength 0.36
  12. Weijing Sun · 2 shared papers, 2020–2026 · strength 0.34
  13. Anup Kasi · 2 shared papers, 2020–2026 · strength 0.34
  14. Osama Mustafa Younis · 1 shared paper, 2025 · strength 0.27
  15. Jiage Qian · 1 shared paper, 2025 · strength 0.25
  16. Sebastiaan Ceuppens · 1 shared paper, 2025 · strength 0.25
  17. Steven A. Soper · 1 shared paper, 2026 · strength 0.23
  18. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.22
  19. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.22
  20. David Robert Spigel · 1 shared paper, 2026 · strength 0.22
  21. Nathan Bahary · 1 shared paper, 2026 · strength 0.22
  22. Susanna Varkey Ulahannan · 1 shared paper, 2026 · strength 0.22
  23. Shubham Pant · 1 shared paper, 2026 · strength 0.22
  24. Nataliya Volodymyrivna Uboha · 1 shared paper, 2026 · strength 0.22
  25. Paul E. Oberstein · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.